Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2021-09-13
Buyer: SYKEHUSINNKJØP HF
Country: NO
Contract type: Supplies
Procedure: Contract award without prior publication
CPV classification: 33600000: Pharmaceutical products
Estimated value: 3800000 NOK
Award criteria: Lowest price

Technical requirements: The Norwegian Hospital Procurement Trust (Norwegian: Sykehusinnkjøp HF), the Pharmaceutical Division (Norwegian abbreviation: LIS) is collecting tenders for pharmaceuticals that are used by the Norwegian health trusts. The Pharmaceutical Division (Norwegian abbreviation: LIS) (Norwegian abbreviation: LIS) has previously published and carried out an open tender contest (LIS 2107 the Oncology contest). The contest included the procurement of active substances in accordance with the tender documentation's appendix 3, the price form. The Norwegian Hospital Procurement Trust did not receive any tenders for the tender notice regarding the delivery of the active substance sorafenib (ATC L01XE05). The contracting authority has published the procurement of Sorafenib in a separate tender contest for active substances where the agreement will begin on 01.03.2022. The current agreement on the active substance expires on 30.09.2021 without an option for extension. Following the implementation of the LIS 2107 Oncology contest, an offer has been made by the the current contract supplier to enter into a temporary agreement for the active substance. The contract period is from 01.10.2021 to 28.02.2022.
The Norwegian Hospital Procurement Trust (Norwegian: Sykehusinnkjøp HF), the Pharmaceutical Division (Norwegian abbreviation: LIS) is collecting tenders for pharmaceuticals that are used by the Norwegian health trusts.  The Pharmaceutical Division (Norwegian abbreviation: LIS) (Norwegian abbreviation: LIS) has previously published and carried out an open tender contest (LIS 2107 the Oncology contest). The contest included the procurement of active substances in accordance with the tender documentation's appendix 3, the price form. The Norwegian Hospital Procurement Trust did not receive any tenders for the tender notice regarding the delivery of the active substance sorafenib (ATC L01XE05). The contracting authority has published the procurement of Sorafenib in a separate tender contest for active substances where the agreement will begin on 01.03.2022. The current agreement on the active substance expires on 30.09.2021 without an option for extension. Following the implementation of the LIS 2107 Oncology contest, an offer has been made by the the current contract supplier to enter into a temporary agreement for the active substance. The contract period is from 01.10.2021 to 28.02.2022.
Based on this information, the Norwegian Hospital Procurement Trust, the Pharmaceutical Division, intends to enter into agreements between the regional health authorities (the Contracting Authorities) and Bayer AS (the Supplier) in a supplementary agreement to LIS 2107. The agreement period is from 01.10.2021 to 28.02.2022. A new new call for tenders for this active substance will therefore not be published.
The health companies that are under the regional health trusts have an option to enter into the contracts. The same applies for non-profit institutions/hospitals with an operational contract with each health region. The Pharmaceutical Division has explored the market situation and is of the opinion that it is not possible to hold a new competition or that a  supplier other than Bayer AS can deliver the product in the same contract period, and that the situation that has occurred is not the contracting authority’s fault, nor something that the contracting authority could predict. The Pharmaceutical Division therefore believes that there are grounds to make the procurement without a competition. Cf. the Public Procurement Regulations §13-4, letter b, no. 3. The Pharmaceutical Division requests that those who have objections to the intended contract award submit feedback before the waiting period expires on 15.09.2021. If no objections are received, a contract will be signed after the waiting period has expired.
The Norwegian Hospital Procurement Trust (Norwegian: Sykehusinnkjøp HF), the Pharmaceutical Division (Norwegian abbreviation: LIS) is collecting tenders for pharmaceuticals that are used by the Norwegian health trusts. The Pharmaceutical Division (Norwegian abbreviation: LIS) (Norwegian abbreviation: LIS) has previously published and carried out an open tender contest (LIS 2107 the Oncology contest). The contest included the procurement of active substances in accordance with the tender documentation's appendix 3, the price form. The Norwegian Hospital Procurement Trust did not receive any tenders for the tender notice regarding the delivery of the active substance sorafenib (ATC L01XE05). The contracting authority has published the procurement of Sorafenib in a separate tender contest for active substances where the agreement will begin on 01.03.2022. The current agreement on the active substance expires on 30.09.2021 without an option for extension. Following the implementation of the LIS 2107 Oncology contest, an offer has been made by the the current contract supplier to enter into a temporary agreement for the active substance. The contract period is from 01.10.2021 to 28.02.2022.
Based on this information, the Norwegian Hospital Procurement Trust, the Pharmaceutical Division, intends to enter into agreements between the regional health authorities (the Contracting Authorities) and Bayer AS (the Supplier) in a supplementary agreement to LIS 2107. The agreement period is from 01.10.2021 to 28.02.2022. A new new call for tenders for this active substance will therefore not be published.
The health companies that are under the regional health trusts have an option to enter into the contracts. The same applies for non-profit institutions/hospitals with an operational contract with each health region. The Pharmaceutical Division has explored the market situation and is of the opinion that it is not possible to hold a new competition or that a  supplier other than Bayer AS can deliver the product in the same contract period, and that the situation that has occurred is not the contracting authority’s fault, nor something that the contracting authority could predict. The Pharmaceutical Division therefore believes that there are grounds to make the procurement without a competition. Cf. the Public Procurement Regulations §13-4, letter b, no. 3. The Pharmaceutical Division requests that those who have objections to the intended contract award submit feedback before the waiting period expires on 15.09.2021. If no objections are received, a contract will be signed after the waiting period has expired.


Winner: Bayer AS
Award value: 3800000